Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CLSP-5282 |
| Synonyms | |
| Therapy Description |
CLSP-5282 is a T-cell engager that targets KRAS G12V presented on HLA-A*03:01, potentially inducing tumor cell killing (Cancer Res (2026) 86 (7_Supplement): 1616). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CLSP-5282 | CLSP5282|CLSP 5282 | CLSP-5282 is a T-cell engager that targets KRAS G12V presented on HLA-A*03:01, potentially inducing tumor cell killing (Cancer Res (2026) 86 (7_Supplement): 1616). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07650357 | Phase I | CLSP-5282 | A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101) | Not yet recruiting | USA | 0 |